{"id":"https://openalex.org/W2990177100","doi":"https://doi.org/10.1182/blood-2019-124437","title":"A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na\u00efve Patients with Higher-Risk Myelodysplastic Syndrome","display_name":"A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na\u00efve Patients with Higher-Risk Myelodysplastic Syndrome","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2990177100","doi":"https://doi.org/10.1182/blood-2019-124437","mag":"2990177100"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-124437","doi":"https://doi.org/10.1182/blood-2019-124437","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124437","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005591514","display_name":"Andrew H. Wei","orcid":"https://orcid.org/0000-0002-7514-3298","observed_orcids":["https://orcid.org/0000-0002-7514-3298"]},"institutions":[{"id":"https://openalex.org/I2801993434","display_name":"The Alfred Hospital","ror":"https://ror.org/01wddqe20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2801993434","https://openalex.org/I4210163178"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Andrew H. Wei","raw_affiliation_strings":["The Alfred Hospital and Monash University, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Alfred Hospital and Monash University, Melbourne, Australia","institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102705548","display_name":"Jacqueline Suen Garcia","orcid":"https://orcid.org/0000-0003-2118-6302","observed_orcids":["https://orcid.org/0000-0003-2118-6302","https://orcid.org/0000-0002-2599-7308"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline S Garcia","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013231204","display_name":"Uma Borate","orcid":"https://orcid.org/0000-0002-4958-4962","observed_orcids":["https://orcid.org/0000-0002-4958-4962"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Uma Borate","raw_affiliation_strings":["Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050688377","display_name":"Chun Yew Fong","orcid":"https://orcid.org/0000-0001-5773-103X","observed_orcids":["https://orcid.org/0000-0001-5773-103X"]},"institutions":[{"id":"https://openalex.org/I4405265871","display_name":"Olivia Newton-John Cancer Research Institute","ror":"https://ror.org/05yncf830","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I196829312","https://openalex.org/I4210158799","https://openalex.org/I4405265871"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Chun Yew Fong","raw_affiliation_strings":["Olivia Newton John Cancer Research Institute, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Olivia Newton John Cancer Research Institute, Melbourne, Australia","institution_ids":["https://openalex.org/I4405265871"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049910941","display_name":"Maria R. Baer","orcid":"https://orcid.org/0000-0002-9499-1348","observed_orcids":["https://orcid.org/0000-0002-9499-1348"]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]},{"id":"https://openalex.org/I4390039317","display_name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","ror":"https://ror.org/01vft3j45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I14285509","https://openalex.org/I4390039317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria R. Baer","raw_affiliation_strings":["University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD","institution_ids":["https://openalex.org/I126744593","https://openalex.org/I4390039317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056927851","display_name":"Florian Nolte","orcid":"https://orcid.org/0000-0002-2765-8940","observed_orcids":["https://orcid.org/0000-0002-2765-8940"]},"institutions":[{"id":"https://openalex.org/I4392738228","display_name":"Stiftung Charit\u00e9","ror":"https://ror.org/016rf0n60","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4392738228","https://openalex.org/I7877124"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Florian Nolte","raw_affiliation_strings":["Department of Hematology and Oncology, Charit\u00e9 University Hospital, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Charit\u00e9 University Hospital, Berlin, Germany","institution_ids":["https://openalex.org/I4392738228","https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023982618","display_name":"Pierre P\u00e9terlin","orcid":"https://orcid.org/0000-0001-5463-6686","observed_orcids":["https://orcid.org/0000-0001-5463-6686"]},"institutions":[{"id":"https://openalex.org/I3019204325","display_name":"Centre Hospitalier Universitaire de Nantes","ror":"https://ror.org/05c1qsg97","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019204325"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Pierre Peterlin","raw_affiliation_strings":["Nantes University Hospital, Department of Haematology, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nantes University Hospital, Department of Haematology, Nantes, France","institution_ids":["https://openalex.org/I3019204325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055703943","display_name":"Joseph Gerard Jurcic","orcid":"https://orcid.org/0000-0002-1671-9998","observed_orcids":["https://orcid.org/0000-0002-1671-9998"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph G. Jurcic","raw_affiliation_strings":["Division of Hematology/Oncology, Columbia University Medical Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Columbia University Medical Center, New York, NY","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031784520","display_name":"Wan\u2010Jen Hong","orcid":"https://orcid.org/0000-0002-0134-4927","observed_orcids":["https://orcid.org/0000-0002-0134-4927"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wan-Jen Hong","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079124367","display_name":"Uwe Platzbecker","orcid":"https://orcid.org/0000-0003-1863-3239","observed_orcids":["https://orcid.org/0000-0003-1863-3239"]},"institutions":[{"id":"https://openalex.org/I4210125843","display_name":"University Hospital Leipzig","ror":"https://ror.org/028hv5492","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210125843"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Platzbecker","raw_affiliation_strings":["Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany","institution_ids":["https://openalex.org/I4210125843"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060015628","display_name":"Olatoyosi M. Odenike","orcid":"https://orcid.org/0000-0002-4027-4124","observed_orcids":["https://orcid.org/0000-0002-4027-4124"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olatoyosi Odenike","raw_affiliation_strings":["Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009328862","display_name":"Martin Dunbar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Dunbar","raw_affiliation_strings":["AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060552570","display_name":"Ying Yin Zhou","orcid":"https://orcid.org/0000-0001-8992-7897","observed_orcids":["https://orcid.org/0000-0001-8992-7897"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Zhou","raw_affiliation_strings":["AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031953045","display_name":"Jason G. Harb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Harb","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039628993","display_name":"Poonam Tanwani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Poonam Tanwani","raw_affiliation_strings":["AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062013948","display_name":"Johannes Ernst Alexander Wolff","orcid":"https://orcid.org/0000-0003-0278-1309","observed_orcids":["https://orcid.org/0000-0003-0278-1309"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johannes E. Wolff","raw_affiliation_strings":["AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114046358","display_name":"Meagan A. Jacoby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299725459","display_name":"Barnes-Jewish Hospital","ror":"https://ror.org/04wyvkr12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299725459","https://openalex.org/I1328499231"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meagan Jacoby","raw_affiliation_strings":["Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine, Richmond Heights, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine, Richmond Heights, MO","institution_ids":["https://openalex.org/I1299725459"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":19,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":46,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"568","last_page":"568"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9940000176429749},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":1.0},{"id":"https://openalex.org/keywords/higher-risk-myelodysplastic-syndromes","display_name":"high-risk myelodysplastic syndrome","score":0.972000002861023},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8659999966621399},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9860000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8579999804496765},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.8679999709129333},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.9229999780654907},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8159999847412109},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.3700000047683716},{"id":"https://openalex.org/keywords/efficacy","display_name":"efficacy","score":0.7860000133514404},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.5979999899864197},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5170000195503235},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.4909999966621399},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.3540000021457672}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9108697175979614},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.8998249769210815},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6590458750724792},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.5531899333000183},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5204927325248718},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5002684593200684},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.429399698972702},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4163548946380615},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.32931822538375854},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32562610507011414},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.14342772960662842},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.1254776418209076},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-124437","doi":"https://doi.org/10.1182/blood-2019-124437","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124437","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3095116203","https://openalex.org/W2891110841","https://openalex.org/W4283326755","https://openalex.org/W4389230978","https://openalex.org/W4389229339","https://openalex.org/W4405039188","https://openalex.org/W3211403252","https://openalex.org/W3095043345","https://openalex.org/W4281828040","https://openalex.org/W3166982387"],"abstract_inverted_index":{"Introduction":[0],"Hypomethylating":[1],"agents":[2],"(HMAs),":[3],"azacitidine":[4],"(Aza)":[5],"or":[6,143,229,290,497,680,947,993,1041],"decitabine,":[7],"are":[8,45,394],"standard":[9],"treatment":[10,1064],"(Tx)":[11],"for":[12,22,36,99,118,146,199,225,247,396,566,595,634,636,655,667,1063],"patients":[13,673],"(pts)":[14],"with":[15,68,139,155,216,240,256,570,698],"higher-risk":[16],"myelodysplastic":[17,1066],"syndrome":[18],"(HR-MDS)":[19],"not":[20,624,1070],"candidates":[21,224],"immediate":[23],"allogeneic":[24,230],"hematopoietic":[25],"stem":[26],"cell":[27],"transplantation":[28],"(HSCT).":[29],"However,":[30],"complete":[31,325],"remission":[32,321,326],"was":[33,170,281,490,572,588,597,612,638,646,657,709],"only":[34,41],"reported":[35],"17%":[37],"receiving":[38],"Aza,":[39],"and":[40,79,113,151,164,175,213,220,305,343,358,386,441,455,477,487,507,530,548,580,621,644,693,748],"half":[42],"the":[43,90,111,168,181,233,248,272,284,307,367,387,467,555,568,607,631],"pts":[44,137,153,215,221,354,365,376,399,412,452,458,553,564,665,697],"alive":[46],"after":[47],"2":[48,152,184,591],"yrs":[49,405],"(Fenaux":[50],"et.":[51,76,85],"al.,":[52,77,86],"2009).":[53],"Venetoclax":[54,1046],"(Ven),":[55],"a":[56,96,127,173,423,430,437,446,689,759,1048],"selective,":[57],"potent,":[58],"orally":[59,246],"bioavailable":[60],"BCL-2":[61,1049],"inhibitor,":[62],"has":[63],"been":[64,356],"shown":[65],"to":[66,172,179,263,302,336,525,610,711,766],"synergize":[67],"HMAs":[69],"in":[70,73,82,366,574,577,584,590,696,715,1054,1065],"preclinical":[71],"studies":[72,81],"HR-MDS":[74,100,717],"(Jilg":[75],"2016)":[78],"clinical":[80],"AML":[83],"(DiNardo":[84],"2016),":[87],"suggesting":[88],"that":[89,1051],"combination":[91,684],"of":[92,116,187,203,211,243,252,271,310,340,349,418,425,432,439,448,520,536,686,704,761,945,991,1039],"Ven+Aza":[93,117,687],"may":[94],"be":[95,712],"promising":[97,694],"approach":[98],"Tx.":[101],"This":[102,1057],"ongoing,":[103],"open-label,":[104],"Phase":[105,183],"1b,":[106],"dose-escalation":[107,174,359,372],"study":[108,123,169,299,556],"is":[109,360,1047,1052,1069],"evaluating":[110],"safety":[112,176,304,388,691],"preliminary":[114],"efficacy":[115,314,695],"Tx-naive":[119],"HR-MDS.":[120,699],"Methods":[121],"The":[122,371,652,683,700],"(NCT02942290)":[124],"initially":[125],"included":[126,135,363,374,390,500],"3-arm":[128],"randomized":[129,369],"cohort.":[130,370],"Data":[131],"from":[132,258,292],"this":[133,604,627,716],"cohort":[134,373],"10":[136,518,558],"treated":[138,154,357,465],"Ven":[140,165,244,274,380,383,705],"(400":[141],"mg":[142,145,260,265,714],"800":[144,166],"28":[147,671],"days)":[148],"+":[149,323,328],"Aza":[150,156,280],"alone.":[157],"Following":[158],"two":[159],"deaths":[160,519],"(Ven":[161,377],"400":[162,264,384,713],"mg=1/5":[163],"mg=1/5),":[167],"amended":[171],"expansion":[177,389],"design":[178],"determine":[180,306],"recommended":[182],"dose":[185,234,275,286,703],"(RP2D)":[186],"Ven+Aza.":[188,311],"Key":[189,312],"inclusion":[190],"criteria":[191],"were":[192,223,238,301,474,483,512,517,523,538,623],"age":[193,403],"\u226518":[194],"yrs,":[195],"no":[196],"prior":[197],"therapy":[198,685],"MDS,":[200],"IPSS":[201,416],"score":[202,210,417,424,431,438,447],"\u22651.5,":[204],"bone":[205],"marrow":[206,324],"blasts":[207],"<20%,":[208],"ECOG":[209],"\u22642,":[212],"excluded":[214],"chronic":[217],"myelomonocytic":[218],"leukemia":[219],"who":[222,559],"undergoing":[226],"intensive":[227],"chemotherapy":[228],"HSCT.":[231],"In":[232,464],"escalation":[235],"portion,":[236],"cohorts":[237,257],"enrolled":[239],"escalating":[241],"doses":[242],"administered":[245,282],"first":[249],"14":[250],"days":[251],"each":[253],"28-day":[254,296],"cycle":[255],"100":[259,378],"daily":[261],"up":[262],"daily.":[266],"Pts":[267],"started":[268],"at":[269,283],"100%":[270],"prescribed":[273],"without":[276,706],"intraindividual":[277],"ramp":[278],"up.":[279],"std":[285],"(75":[287],"mg/m2,":[288],"subcutaneously":[289],"IV)":[291],"Day":[293],"1-7":[294],"per":[295],"cycle.":[297],"Primary":[298],"objectives":[300],"evaluate":[303],"RPTD":[308],"schedule":[309],"secondary":[313],"outcomes":[315],"include":[316],"objective":[317],"response":[318,337,341],"rate":[319],"(ORR[complete":[320],"(CR)":[322,571],"(mCR)":[327],"partial":[329],"remission]),":[330],"progression":[331,587],"free":[332],"survival":[333,345],"(PFS),":[334],"time":[335,609],"(TTR),":[338],"duration":[339],"(DOR),":[342],"overall":[344,415],"(OS).":[346],"Results":[347,393],"As":[348],"April":[350],"9,":[351],"2019,":[352],"59":[353,398],"have":[355],"complete.":[361],"These":[362],"12":[364],"initial":[368],"25":[375],"mg=8,":[379],"200":[381],"mg=9,":[382],"mg=8)":[385],"22":[391,578],"pts.":[392,592],"presented":[395],"all":[397],"[75%":[400],"male,":[401],"median":[402,608],"71":[404],"(range":[406,600,615],"26-85)].":[407],"At":[408,603],"baseline,":[409],"15":[410],"(25%)":[411],"had":[413,422,429,436,445,453,459],"an":[414,942,988,1036,1071],"1.5,":[419],"29":[420],"(49%)":[421],"2,":[426],"8":[427],"(14%)":[428],"2.5,":[433],"6":[434],"(10%)":[435],"3.0,":[440],"1":[442],"(2%)":[443],"pt":[444],"3.5.":[449],"Eleven":[450],"(19%)":[451],"intermediate":[454],"24":[456],"(41%)":[457],"poor":[460],"baseline":[461],"cytogenetic":[462],"risk.":[463],"pts,":[466],"most":[468],"common":[469],"treatment-emergent":[470],"adverse":[471],"events":[472],"(TEAE's)":[473],"anemia,":[475],"neutropenia,":[476],"thrombocytopenia":[478,503],"(Table).":[479],"Common":[480],"gastrointestinal":[481],"symptoms":[482],"constipation,":[484],"nausea,":[485],"diarrhea,":[486],"vomiting.":[488],"Infection":[489],"predominantly":[491],"febrile":[492,513],"neutropenia.":[493],"Predominant":[494],"Grade":[495],"3":[496],"4":[498,522],"AEs":[499],"neutropenia":[501,514],"(61%),":[502],"(39%),":[504],"leukopenia":[505],"(31%),":[506],"anemia":[508],"(20%).":[509],"Major":[510],"SAEs":[511],"(31%).":[515],"There":[516],"which":[521,1068],"due":[524],"infections":[526],"(pneumonia-2,":[527],"neutropenic":[528],"sepsis-1":[529],"septic":[531],"shock-":[532],"1).":[533],"Other":[534],"causes":[535],"death":[537,550],"multiorgan":[539],"failure":[540,543],"(n=1),":[541,544],"respiratory":[542],"progressive":[545],"disease":[546,582],"(n=3),":[547],"unexplained":[549],"(n=1).":[551],"Twenty":[552],"discontinued":[554],"including":[557],"underwent":[560],"transplantation.":[561],"Among":[562,663],"57":[563],"evaluable":[565],"response,":[567],"ORR":[569,596,637],"documented":[573],"18,":[575],"mCR":[576],",":[579],"stable":[581],"(SD)":[583],"11.":[585],"Disease":[586],"observed":[589],"Median":[593,618],"TTR":[594],"1.0":[598],"mos":[599,614],"0.7-3.5":[601],"mos).":[602],"data":[605],"cut,":[606],"FU":[611],"4.3":[613],"3.3-6.5":[616],"months).":[617],"DOR,":[619],"PFS":[620,645],"OS":[622,656],"reached.":[625],"With":[626],"short":[628],"follow":[629],"up,":[630],"12-mo":[632],"estimates":[633],"DOR":[635],"74%":[639,658],"(95%":[640,648,659],"CI:":[641,649,660],"34%,":[642],"92%)":[643],"59%":[647],"31%,":[650],"79%).":[651],"18-mo":[653],"estimate":[654],"50%,":[661],"87%).":[662],"56":[664],"eligible":[666],"hematological":[668],"improvement":[669],"(HI),":[670],"(50%)":[672],"achieved":[674],"HI":[675],"as":[676],"either":[677],"HI-erythroid,":[678],"HI-platelet,":[679],"HI-neutrophil.":[681],"Conclusion":[682],"demonstrated":[688],"tolerable":[690],"profile":[692],"maximum":[701],"tolerated":[702],"dose-limiting":[707],"toxicities":[708],"determined":[710],"population.":[718],"Disclosures":[719],"Wei:":[720],"Pfizer:":[721,798],"Honoraria;":[722,726,769,775],"Astellas:":[723,808,820,843,861],"former":[724,753],"employee,":[725,754],"Novartis:":[727,790,859,894],"Honoraria,":[728,732,736,740,744,771,833,837,928,933],"Research":[729,733,737,741,745,772,779,782,804,812,815,818,821,824,827,830,834,838,857,862,866,870,874,877,881,885,889,892,895,898,902,906,909,913,916,929,934,950,953,956,960,963,967,971,975,978,982],"Funding;":[730,734,738,742,746,773,780,813,816,819,822,825,828,835,858,863,867,871,875,878,882,890,893,896,899,903,907,910,914,930,935,951,954,957,961,964,968,972,976,979,983],"AstraZeneca:":[731],"AbbVie:":[735,786,897,984],"Amgen:":[739,802],"Servier:":[743],"Walter":[747],"Eliza":[749],"Hall":[750],"Institute:":[751],"Other:":[752,999,1005,1011,1017,1023],"Patents":[755],"&":[756],"Royalties:":[757],"receives":[758],"fraction":[760],"its":[762],"royalty":[763],"stream":[764],"related":[765],"venetoclax;":[767],"Macrogenics:":[768],"Celgene:":[770,836,855,900,931],"Genentech:":[774,781,876],"Janssen:":[776],"Honoraria.":[777,938],"Garcia:Abbvie:":[778],"Funding.":[783,831,839,886,917],"Borate:Pfizer:":[784],"Consultancy;":[785,787,789,791,842,844,847,851,854,860,1031],"Takeda:":[788,817],"Daiichi":[792,872],"Sankyo:":[793,873],"Consultancy.":[794,809,849],"Fong:Novartis:":[795],"Speakers":[796,800,806,1027],"Bureau;":[797,801,807,1028],"Consultancy,":[799,803,856,888,901,905,927,932,937,985],"Funding,":[805],"Baer:Al":[810],"Therapeutics:":[811,880],"Kite:":[814],"Abbvie:":[823,936],"Forma:":[826],"Incyte:":[829,962],"Nolte:Novartis:":[832],"Peterlin:AbbVie":[840],"Inc:":[841,853,997,1003,1009,1015,1021],"Jazz":[845,1032],"Pharma:":[846,974,1033],"Daiichi-Sankyo:":[848],"Jurcic:Incyte:":[850],"AbbVie":[852],"Syros":[864],"Pharmaceuticals:":[865,869,981],"Actinium":[868],"Forma":[879],"Kura":[883],"Oncology:":[884,970],"Garcia-Manero:Amphivena:":[887],"Helsinn:":[891],"Astex:":[904],"Onconova:":[908],"H3":[911],"Biomedicine:":[912],"Merck:":[915],"Hong:Roche:":[918],"Equity":[919,924],"Ownership;":[920],"Genentech":[921],"Inc.:":[922],"Employment,":[923,998,1004,1010,1016,1022],"Ownership.":[925],"Platzbecker:Novartis:":[926],"Odenike:Celgene:":[939],"Membership":[940,986,1034],"on":[941,987,1035,1061],"entity's":[943,989,1037],"Board":[944,990,1038],"Directors":[946,992,1040],"advisory":[948,994,1042],"committees,":[949],"Agios:":[952],"Oncotherapy:":[955],"Astra":[958],"Zeneca:":[959],"Gilead":[965],"Sciences:":[966],"Janssen":[969],"NS":[973],"CTI/Baxalta:":[977],"Astex":[980],"committees.":[995,1043],"Dunbar:AbbVie":[996],"Stock/stock":[1000,1006,1012,1018,1024],"options.":[1001,1007,1013,1019,1025],"Zhou:AbbVie":[1002],"Harb:AbbVie":[1008],"Tanwani:AbbVie":[1014],"Wolff:AbbVie":[1020],"Jacoby:Celgene:":[1026],"Novo":[1029],"Nordisk:":[1030],"OffLabel":[1044],"Disclosure:":[1045],"inhibitor":[1050],"FDA-approved":[1053],"some":[1055],"indications.":[1056],"presentation":[1058],"will":[1059],"focus":[1060],"venetoclax":[1062],"syndromes,":[1067],"approved":[1072],"indication.":[1073]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":17}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-12-05T00:00:00"}